(BED) is the most prevalent eating disorder in adults and a frequent cause of obesity-related medical morbidity, yet it remains under-recognized in general psychiatric and primary care practice. places BED among the feeding and eating disorders, defined by recurrent episodes of loss-of-control eating without the compensatory behaviors that characterize . The condition is strongly comorbid with mood, anxiety, substance use, and , and it carries elevated risk of metabolic , type 2 diabetes, and cardiovascular disease. First-line treatment is structured psychotherapy — in particular — with lisdexamfetamine the only US Food and Drug Administration-approved pharmacotherapy for moderate-to-severe disease. The clinical bottom line: screen patients with obesity or unexplained weight cycling, anchor the diagnosis in loss-of-control rather than quantity eaten, and lead treatment with CBT augmented by pharmacotherapy when indicated.
BED is the most common eating disorder in the United States and worldwide, with prevalence exceeding and bulimia nervosa combined.[1-2] Recognition lags prevalence because patients rarely volunteer the symptom and clinicians rarely screen.
Prevalence
- Lifetime prevalence in US adults approximately 2.8%, with 12-month prevalence approximately 1.2%.[1]
- Global pooled lifetime prevalence estimated near 1.9% in a large World Health Organization survey program.[2]
- Prevalence among bariatric-surgery candidates and weight-loss clinic attendees ranges from 15% to 30%.[3]
Demographics
- Female-to-male ratio approximately 1.75:1, narrower than for bulimia nervosa or anorexia nervosa.[1-2]
- Mean age of onset is in the early to mid-20s, later than for bulimia nervosa.[1]
- BED occurs across racial, ethnic, and socioeconomic groups at comparable rates, in contrast to historical assumptions.[2,4]
Comorbidity
- Approximately 79% of individuals with BED meet criteria for at least one other lifetime psychiatric disorder.[1]
- Mood disorders, , and substance use disorders are the most frequent comorbidities.[1-2]
- is overrepresented in BED, with shared phenotypes of impulsivity and reward dysregulation.[5]
- Lifetime suicidal ideation is reported in roughly 25–35%, with suicide attempts in approximately 12–15%.[1,6]
Medical burden
- BED is strongly associated with obesity but not synonymous with it; roughly half of individuals with BED have a body mass index in the obese range.[3-4]
- Independent of body weight, BED elevates risk for type 2 diabetes, dyslipidemia, hypertension, and metabolic syndrome.[3,7]
- BED is associated with elevated all-cause health-care utilization and reduced health-related quality of life.[4,7]
BED arises from interacting genetic, neurobiological, developmental, and environmental contributors that converge on impaired regulation of appetitive behavior. Modern formulations emphasize reward-system hypersensitivity coupled with deficient inhibitory control.[5,8]
Neurobiology
- Functional imaging shows heightened ventral striatal and orbitofrontal cortex response to food cues, with attenuated prefrontal cortical engagement during inhibitory tasks.[8]
- Dopaminergic , particularly the , is implicated in the loss-of-control phenotype, paralleling findings in substance use disorders.[5,8]
- Dysregulation of the hypothalamic appetite-control axis, including leptin and ghrelin signaling, is described but inconsistent across studies.[8]
- Serotonergic dysfunction has been proposed as a mediator of mood-driven binge episodes, supporting the rationale for SSRI trials.[9]
Genetics
- Twin studies estimate heritability of BED at approximately 40–60%.[10]
- Genome-wide association studies are limited by sample size; candidate signals overlap with those identified for obesity and ADHD.[10]
- First-degree relatives of probands with BED show elevated rates of BED and obesity, consistent with shared familial liability.[10]
Developmental and environmental factors
- Childhood adversity — particularly emotional abuse and neglect — is reported at elevated rates and predicts earlier onset and greater severity.[6,11]
- Weight-related teasing, body-dissatisfaction trajectories, and dieting history in adolescence are robust prospective risk factors.[11]
- Food insecurity is independently associated with binge-eating behavior, complicating socioeconomic interpretations of risk.[12]
Integrative model
- Current models conceptualize BED as a transdiagnostic disorder of affect regulation in which palatable food serves as a maladaptive emotion-regulation strategy in a vulnerable reward system.[5,8]
- This framing rationalizes the therapeutic targeting of both affective triggers (CBT, IPT) and reward-impulse pathways (lisdexamfetamine).[13-14]
DSM-5-TR locates BED among the feeding and eating disorders and was first recognized as a stand-alone diagnosis in DSM-5 (2013).[15] The diagnosis hinges on recurrent loss-of-control eating without compensatory behaviors.
Core criteria
- Recurrent binge-eating episodes, each defined by both eating an amount of food clearly larger than most people would eat in a similar period and under similar circumstances, and a sense of loss of control over eating during the episode.[15]
- Binge episodes are associated with at least three of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts when not physically hungry; eating alone because of embarrassment; and feeling disgusted, depressed, or very guilty afterward.[15]
- Marked distress regarding binge eating.[15]
- Frequency of at least one binge episode per week for three months.[15]
- Absence of recurrent inappropriate compensatory behavior characteristic of bulimia nervosa, and the binge eating does not occur exclusively during the course of bulimia nervosa or anorexia nervosa.[15]
Severity specifiers, based on weekly binge frequency:
- Mild: 1–3 episodes per week.[15]
- Moderate: 4–7 episodes per week.[15]
- Severe: 8–13 episodes per week.[15]
- Extreme: 14 or more episodes per week.[15]
Course specifiers
- In partial remission: after full criteria were previously met, binge-eating episodes occur at a frequency less than once per week for a sustained period.[15]
- In full remission: after full criteria were previously met, none of the criteria have been met for a sustained period.[15]
BINGE
Big amounts, In a discrete period, No control, Guilt or disgust afterward, Eating despite no hunger — the five clinical markers that flag a probable binge episode.[15]
ICD-11 differences
- also lists binge-eating disorder as a distinct entity under feeding and eating disorders (chapter 06), reflecting convergence with DSM-5-TR.[16]
- ICD-11 emphasizes subjective loss of control and allows subjective binge episodes — where the amount may not be objectively large — to count toward diagnosis when associated distress is present, a more flexible threshold than DSM-5-TR.[16]
- ICD-11 does not require the three-month duration threshold used by DSM-5-TR.[16]
A common clinical mistake is to confuse a large eating episode with a binge. The DSM-5-TR diagnosis requires the subjective experience of loss of control, not merely the quantity consumed.[15]
BED presents with a stereotyped behavioral pattern embedded in a broader picture of weight cycling, shame, and affective dysregulation. Patients typically conceal the behavior, so directed inquiry is essential.[4,17]
Symptom clusters
- Behavioral: eating rapidly, eating in secrecy, hoarding or hiding food, eating to the point of physical discomfort, and recurrent dieting between binges.[17]
- Affective: pre-binge tension or dysphoria, transient relief during eating, post-binge guilt and self-disgust.[17]
- Cognitive: overvaluation of shape and weight is common but not required for diagnosis, in contrast to bulimia nervosa where it is more pronounced.[4,17]
Course and prodrome
- A prodrome of restrictive dieting, weight-related teasing, and subthreshold loss-of-control eating in adolescence is typical.[11,17]
- Onset is usually in late adolescence or early adulthood, with a chronic-relapsing course in untreated patients.[1,17]
- Spontaneous remission rates are modest; without treatment, persistence over 5 years is common, although severity often fluctuates.[17]
Prototypical presentation
- A patient in their 20s or 30s presents with obesity, a history of repeated diet attempts, and weight cycling, often with a long-standing pattern of eating large quantities of palatable foods in private over a 1–2 hour window, followed by guilt and renewed dietary restraint.[4,17]
Atypical presentations
- Normal-weight BED occurs in roughly half of patients; absence of obesity does not exclude the diagnosis.[3-4]
- In male patients, binge episodes more often co-occur with alcohol use and may be less likely to involve overvaluation of body shape.[2,4]
- Adolescents may report loss-of-control eating without yet meeting the size or frequency thresholds; this is treated as a clinically significant prodrome.[11]
Red flags requiring escalation
- Rapid unexplained weight gain or loss, electrolyte abnormalities, or syncope warrant medical work-up to exclude purging behavior the patient has not disclosed.[18]
- Suicidal ideation or active self-harm requires standard psychiatric risk assessment.[6]
- Diabetes with binge-driven glycemic instability or insulin omission requires coordinated endocrine and psychiatric care.[7]
The differential centers on distinguishing BED from other feeding and eating disorders and from medical or substance-induced mimics. Loss-of-control eating is non-specific; compensatory behavior, weight trajectory, and motivational context drive the diagnosis.[15,17]
Other eating disorders
- Bulimia nervosa shares binge episodes but is defined by recurrent inappropriate compensatory behaviors (self-induced vomiting, laxative misuse, fasting, or excessive exercise); BED explicitly excludes such behaviors.[15]
- Anorexia nervosa, binge-eating/purging subtype, requires low body weight and the disturbance in experiencing one's body weight or shape; weight is usually preserved or elevated in BED.[15]
- involves restrictive eating without body-image preoccupation and is not characterized by binge episodes.[15]
- Other specified feeding or eating disorder (e.g., subthreshold BED with binges less than weekly or for less than 3 months) is the residual category when frequency or duration is insufficient.[15]
Mood and impulse-related conditions
- Major depressive disorder with overeating during episodes can mimic BED; the differentiator is the loss-of-control quality and episodic structure of binges, not appetite increase alone.[1,17]
- Bipolar disorder can involve hyperphagia during depressive episodes; episodic mood pattern guides diagnosis.[1]
- ADHD frequently co-occurs and shares impulsive eating phenotypes; both can be diagnosed when criteria are independently met.[5]
Medical mimics
- Hypothyroidism can drive weight gain and dysphoria; check thyroid function in any new presentation.[18]
- Hypothalamic lesions (craniopharyngioma, Prader-Willi syndrome) can produce hyperphagia without the subjective loss-of-control structure characteristic of BED.[18]
- Diabetes with hypoglycemia-driven eating episodes is distinguished by glycemic context and absence of post-episode guilt or shame.[7]
- Sleep-related eating disorder involves nocturnal eating with reduced awareness during partial arousals from sleep and lacks the daytime loss-of-control phenotype.[19]
Substance- and medication-induced presentations
- Cannabis use can produce hyperphagia ("munchies") without the loss-of-control phenotype.[18]
- Second-generation antipsychotics, particularly olanzapine and clozapine, drive appetite increase and weight gain that can be mistaken for primary BED.[20]
- Corticosteroids and some anticonvulsants increase appetite and may precipitate or unmask binge behavior.[20]
| Feature | Binge-eating disorder | Bulimia nervosa | Anorexia nervosa, binge/purge |
|---|---|---|---|
| Binge episodes | Required, ≥1/week ×3 months | Required, ≥1/week ×3 months | Required during binge/purge episodes |
| Compensatory behaviors | Absent | Required and recurrent | Required and recurrent |
| Body weight | Often elevated or normal | Usually normal | Significantly low |
| Body-image disturbance | Variable; not required | Prominent | Required |
| Mean age of onset | Early–mid 20s | Late teens–early 20s | Mid-teens |
| First-line treatment | CBT-E; lisdexamfetamine if moderate-severe [13,14] | CBT-E; fluoxetine 60 mg [21] | Weight restoration; family-based therapy in adolescents [22] |
Assessment is structured around a focused clinical interview, validated screening, and targeted medical work-up. Clinicians under-detect BED because they do not ask; explicit, non-judgmental inquiry is the single highest-yield maneuver.[4,17]
Interview approach
- Open with normalizing language: many patients with weight concerns experience episodes of loss-of-control eating, and the clinician is asking to help.[17]
- Probe both objective binges (large amounts in a discrete period) and subjective binges (loss-of-control with smaller amounts).[15,17]
- Quantify frequency, duration, and triggers; distinguish grazing from discrete binge episodes.[17]
- Screen for compensatory behaviors explicitly, including covert behaviors the patient may not volunteer.[17]
Mandatory history
- Weight trajectory and dieting history, including weight cycling and bariatric history.[3-4]
- Comorbid mood, anxiety, ADHD, substance use, and trauma history.[1,5-6]
- Medication history with attention to weight-affecting agents.[20]
- Family history of eating disorders, obesity, and mood disorders.[10]
Physical exam
- Vital signs and body mass index at every visit.[18]
- Examine for signs suggestive of undisclosed purging (parotid enlargement, Russell sign, dental erosion); their absence does not rule out BED but their presence reframes the diagnosis toward bulimia nervosa.[18]
- Acanthosis nigricans, central obesity, and waist circumference support metabolic risk assessment.[7]
Validated rating scales
- The (EDE-Q) is widely used for symptom severity and treatment monitoring.[23]
- The Binge Eating Scale (BES) is a 16-item self-report instrument calibrated for BED severity.[24]
- The 7-item Binge-Eating Disorder Screener (BEDS-7) is a brief, validated tool for primary-care or psychiatric screening.[25]
- Comorbidity screening with the , , and ADHD-focused tools is recommended on first evaluation.[1,5]
ASK BED
Amount large, Sense of loss of control, Kept secret, Bothered by it (distress), Episodes weekly, Diet between — the six prompts to cover when screening for BED at a single visit.[15,17]
Labs and imaging
- Baseline metabolic panel, lipid panel, hemoglobin A1c, and thyroid-stimulating hormone are appropriate in most new presentations.[7,18]
- Electrolytes are particularly useful when undisclosed purging is suspected.[18]
- Imaging is not routinely indicated; obtain only when suggest a hypothalamic or structural lesion.[18]
What NOT to order
Treatment leads with structured psychotherapy and adds pharmacotherapy when severity, comorbidity, or psychotherapy response warrants. Evidence supports a hierarchy with CBT at the apex and lisdexamfetamine as the only FDA-approved drug specifically for BED.[13-14,17]
Pharmacotherapy
- lisdexamfetamine 30-70 mg PO QD is FDA-approved for moderate-to-severe BED in adults; pivotal trials showed significant reductions in binge days and remission rates compared with placebo.[14]
- Lisdexamfetamine is a Schedule II controlled substance; screen for cardiovascular risk, history of stimulant misuse, and uncontrolled hypertension before prescribing.[14]
- topiramate 50-400 mg PO QD reduces binge frequency and body weight in randomized trials but is limited by cognitive adverse effects, paresthesias, and teratogenicity.[26]
- (e.g., fluoxetine 60 mg PO QD, sertraline 50-200 mg PO QD) reduce binge frequency modestly and can be useful when comorbid depression or anxiety drives the clinical picture; weight-loss effect is small and inconsistent.[9,17]
- Evidence suggests SSRI effect on binge frequency is smaller than for bulimia nervosa and may not persist after discontinuation.[9]
- Some experts recommend bupropion 300 mg PO QD in BED with comorbid depression or smoking cessation goals, though high-quality evidence for binge outcomes is lacking.[17]
- Limited evidence suggests glucagon-like peptide-1 receptor agonists may reduce binge frequency, but data are early and they are not approved for this indication.[27]
Psychotherapy
- Strong evidence supports CBT for BED (CBT-E or the original Fairburn protocol) as first-line; it reduces binge frequency and improves abstinence rates more than waitlist or behavioral weight loss alone.[13,28]
- Guided self-help CBT, including therapist-supported online or workbook-based programs, is effective for mild-to-moderate BED and expands access.[28]
- Interpersonal psychotherapy (IPT) shows comparable long-term efficacy to CBT in head-to-head trials, supporting its use when interpersonal triggers dominate.[13,28]
- Dialectical behavior therapy adapted for BED reduces binge frequency in trials, particularly when emotion dysregulation is prominent.[29]
- Behavioral weight loss alone reduces weight modestly but is inferior to CBT for binge-frequency outcomes.[28]
Neuromodulation
- targeting the dorsolateral has shown promising early effects on food craving and binge frequency, but evidence is preliminary.[30]
- Transcranial direct current stimulation is under investigation with similarly preliminary data.[30]
- is investigational and confined to research protocols.[30]
Adjunctive
- Nutritional counseling with a dietitian experienced in eating disorders supports regular eating patterns and counters dietary restraint that perpetuates the binge cycle.[17,28]
- Treatment of comorbid ADHD with stimulants or atomoxetine can independently improve binge outcomes when ADHD is present.[5]
- Bariatric surgery is not contraindicated by BED but requires preoperative psychiatric evaluation and postoperative monitoring for symptom re-emergence.[3]
- Peer-support and structured group programs (Overeaters Anonymous, hospital-based groups) are adjuncts, not substitutes for evidence-based treatment.[17]
Lisdexamfetamine carries cardiovascular risk, including elevated heart rate and blood pressure, and a boxed warning for stimulant misuse and dependence; it is contraindicated in patients with structural cardiac abnormalities or a history of stimulant use disorder.[14]
When a patient with BED has comorbid major depressive disorder and obesity, starting with bupropion or topiramate-containing regimens avoids the weight-gain liability of mirtazapine or paroxetine while addressing both conditions.[17]
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| CBT (CBT-E) | Multiple RCTs and meta-analyses vs waitlist and behavioral weight loss [13,28] | Reduced binge frequency; higher remission rates; durable through 1–2 years | None significant; time and access burden | high | First-line across guidelines |
| Interpersonal psychotherapy | RCTs vs CBT and behavioral weight loss [13,28] | Comparable binge-frequency reduction to CBT at long-term follow-up | Therapy time burden | moderate | Reasonable alternative when interpersonal triggers prominent |
| Guided self-help CBT | RCTs vs waitlist and full CBT [28] | Effective for mild-moderate severity; expands access | Lower retention than therapist-led CBT | moderate | Useful in stepped-care models |
| Lisdexamfetamine | Pivotal phase 3 RCTs vs placebo [14] | Reduced binge days/week; remission; modest weight loss | Insomnia, decreased appetite, dry mouth, elevated heart rate/BP; misuse risk | high | Only FDA-approved drug for moderate-severe BED |
| Topiramate | RCTs vs placebo, often with CBT [26] | Reduced binge frequency and body weight | Paresthesia, cognitive dulling, kidney stones, teratogenicity | moderate | Off-label; titrate slowly |
| SSRIs (fluoxetine, sertraline) | RCTs vs placebo [9,17] | Modest reduction in binge frequency; treats comorbid mood/anxiety | GI, sexual dysfunction, | moderate | Effect smaller than in bulimia nervosa |
| GLP-1 receptor agonists | Small RCTs and open-label studies [27] | Possible reduction in binge frequency; weight loss | GI side effects; cost; not approved for BED | low | Investigational for BED |
| / tDCS | Small RCTs targeting DLPFC [30] | Possible reduction in craving and binges | Headache, scalp discomfort | low | Insufficient evidence for routine use |
The harms of BED treatment fall into two domains: adverse effects of specific pharmacotherapies, and limitations of the evidence base supporting current recommendations. Most treatment-emergent harms are manageable, but several merit explicit pre-treatment counseling.[14,17,26]
Common adverse effects
- Lisdexamfetamine commonly causes dry mouth, decreased appetite, insomnia, and increased heart rate; many resolve with dose titration.[14]
- Topiramate commonly causes paresthesia, cognitive slowing ("word-finding difficulty"), fatigue, and taste alterations, particularly with carbonated beverages.[26]
- SSRIs commonly cause gastrointestinal upset, sexual dysfunction, and sleep disruption; weight effects are variable.[9]
Serious or rare adverse effects
- Lisdexamfetamine has a boxed warning for stimulant misuse, dependence, and serious cardiovascular events including sudden death in patients with structural cardiac disease.[14]
- Topiramate is teratogenic (oral clefts in first-trimester exposure) and increases risk of kidney stones, acute angle-closure glaucoma, and metabolic acidosis.[26]
- SSRIs carry a boxed warning for suicidality in patients under 25 and risk of in combinations.[9]
- All antidepressants and stimulants require attention to drug-drug interactions, particularly with monoamine oxidase inhibitors.[9,14]
Monitoring and discontinuation
- Lisdexamfetamine requires baseline and ongoing blood pressure, heart rate, and weight monitoring; reassess cardiovascular risk before titration.[14]
- Topiramate requires periodic monitoring for serum bicarbonate (metabolic acidosis) and renal stones.[26]
- SSRIs should be tapered to avoid discontinuation syndrome.[9]
Limitations of the evidence base
- Most pharmacotherapy trials in BED enrolled predominantly female, middle-aged, white participants; generalizability to other groups is limited.[14,17]
- Trial duration is typically 12–24 weeks; long-term efficacy and relapse data are sparse, especially for pharmacotherapy.[14]
- Comparative-effectiveness data — particularly between lisdexamfetamine and CBT — are limited, and combination-treatment trials are few.[14,28]
- Outcome measures vary across trials; the field has not standardized on remission definitions, limiting cross-trial comparisons.[17,28]
- Publication bias and industry sponsorship are particularly relevant for the lisdexamfetamine evidence base.[14]
BED occurs across the lifespan, in pregnancy, and in patients with high medical complexity. Treatment selection adjusts to developmental stage, reproductive status, and comorbid disease.[17,22]
Pediatric and adolescent
- BED can be diagnosed in children and adolescents; loss-of-control eating in youth predicts future BED and obesity.[11]
- Family-based approaches and CBT adapted for adolescents are preferred; pharmacotherapy data in this age group are limited.[22]
- Lisdexamfetamine is not FDA-approved for BED in children; use in adolescents requires careful risk-benefit discussion.[14]
Geriatric
- BED in older adults is under-recognized; sarcopenic obesity and polypharmacy complicate management.[17]
- Stimulants warrant heightened cardiovascular caution; topiramate cognitive effects are more pronounced in older patients.[14,26]
Perinatal
- BED behaviors often improve during pregnancy and may recur postpartum; perinatal mental health follow-up is appropriate.[17]
- Topiramate is contraindicated in pregnancy due to teratogenicity; lisdexamfetamine in pregnancy lacks adequate human data and is generally avoided.[14,26]
- SSRIs may be continued with risk-benefit counseling; fluoxetine and sertraline have the most reproductive safety data.[9]
Comorbid medical illness
- Type 2 diabetes with BED requires coordinated care; glycemic instability often improves with BED treatment.[7]
- Cardiovascular disease alters pharmacotherapy choice; stimulants are typically avoided, and topiramate or SSRIs become first-line drug options.[14,17]
- Bariatric surgery candidates with active BED should be identified preoperatively; BED is not an absolute contraindication but predicts poorer postoperative weight outcomes if untreated.[3]
Comorbid substance use
- Co-occurring substance use disorders are common and complicate stimulant prescribing; lisdexamfetamine is contraindicated in active stimulant use disorder.[14]
- Treat substance use disorder concurrently rather than sequentially; integrated care improves both outcomes.[17]
Cultural considerations
- BED occurs across racial and ethnic groups at comparable rates, but presentation, help-seeking, and access to care vary; culturally responsive assessment reduces under-diagnosis.[2,4]
- Stigma around weight and around mental illness shapes disclosure; framing BED as a treatable medical condition reduces shame and improves engagement.[17]
With evidence-based treatment, a majority of patients achieve clinically meaningful improvement; without treatment, the course is chronic with fluctuating severity. Long-term outcomes are better than for anorexia nervosa.[1,17]
Natural history
- Untreated BED tends to be chronic with waxing and waning severity; spontaneous full remission is uncommon over short follow-up.[1,17]
- Five-year persistence is reported in roughly 25–50% of community samples, with another fraction transitioning to other specified eating disorders or subthreshold presentations.[17]
Response and remission
- CBT achieves abstinence from binge eating in approximately 50% of completers at end-of-treatment, with durable effects through 1–2 years.[13,28]
- Lisdexamfetamine 50–70 mg daily produces a roughly 40% abstinence rate at 12 weeks in pivotal trials, versus approximately 14% on placebo.[14]
- Comorbid mood and anxiety disorders typically improve with successful BED treatment, but persistent comorbidity predicts relapse.[1,17]
Suicide risk
- Lifetime suicidal ideation is elevated in BED; suicide attempts occur in approximately 12–15% of affected individuals.[1,6]
- Risk is concentrated in patients with comorbid mood, substance use, and trauma histories; routine suicide screening is appropriate.[6]
Functional outcome
- BED is associated with reduced work productivity, impaired social functioning, and lower health-related quality of life.[4,7]
- Effective treatment improves quality-of-life measures alongside binge-frequency reductions.[13-14]
Mortality
Acute presentations in BED are uncommon but well-defined; the clinician's task is to recognize the medical and psychiatric crises that require escalation. Most BED is managed in the outpatient setting.[17-18]
Hospitalization criteria
- Acute suicidal ideation with intent or plan, particularly with comorbid major depression or substance use, warrants inpatient psychiatric admission per standard criteria.[6]
- Severe medical complications (electrolyte disturbance, acute cardiovascular event, decompensated diabetes) may require medical or combined medical-psychiatric admission.[18]
- Diagnostic uncertainty about undisclosed purging or rapid weight changes can justify a short observation admission.[18]
Suicide risk markers
- Comorbid major depression, substance use disorder, , and history of childhood abuse elevate risk.[6]
- Active binge-purge transitions and rapid worsening of body-image distress can precede self-harm and warrant frequent reassessment.[6]
Agitation management
- Agitation is not characteristic of BED; when it occurs, evaluate for comorbid mood, psychotic, or substance-related causes and treat per general psychiatric emergency principles.[18]
Safety-relevant comorbid presentations
- Insulin omission in patients with type 1 diabetes and BED (sometimes called "diabulimia" in lay literature) is life-threatening and requires urgent endocrine and psychiatric involvement; the behavior is technically a compensatory behavior more characteristic of bulimia nervosa, but it occurs in BED with comorbid diabetes.[7,18]
- Stimulant misuse for weight control should be screened for in any patient receiving lisdexamfetamine.[14]
Loss-of-control eating with self-induced vomiting, laxative misuse, or insulin omission reclassifies the diagnosis toward bulimia nervosa or anorexia nervosa; this changes the safety profile, monitoring, and treatment priorities — including avoidance of bupropion when purging is suspected because of elevated seizure risk.[15,18,21]
BED has been a recognized diagnosis for only a little over a decade in DSM-5, and several practice-shaping questions remain unsettled. Clinicians should hold these in mind when counseling patients and when reading new evidence.[15,17]
Diagnostic threshold
- The DSM-5-TR requirement of one binge per week for three months is pragmatic but somewhat arbitrary; subthreshold presentations cause real distress and impairment.[15,17]
- ICD-11 allows subjective binges and does not require the three-month threshold, leading to nominally higher prevalence estimates and earlier identification.[16]
Pharmacotherapy positioning
- Whether lisdexamfetamine or CBT should be first-line is contested; guidelines generally favor psychotherapy first, but real-world access and patient preference often invert this hierarchy.[13-14,17]
- The role of combination CBT plus lisdexamfetamine is under-studied despite being a common clinical pattern.[14,28]
- The durability of pharmacotherapy response after discontinuation is uncertain; many patients experience symptom return.[14]
GLP-1 receptor agonists
- Semaglutide, liraglutide, and tirzepatide are increasingly used for obesity and have been informally adopted for binge-related eating, but evidence in BED is limited to small trials and post-hoc analyses.[27]
- Whether weight loss in these patients reduces binge frequency independently of any direct CNS effect is unresolved.[27]
Relationship to obesity
- The boundary between BED and "food addiction" or "compulsive overeating" frameworks remains conceptually contested; food-addiction constructs are not DSM diagnoses.[5,17]
- Bariatric surgery in BED patients can produce dramatic short-term improvements that may not be durable; the optimal preoperative psychiatric pathway is debated.[3]
Health equity
- BED is the most prevalent eating disorder in the United States, with lifetime prevalence in adults around 2.8%.[1]
- Diagnosis requires recurrent binge eating (≥1/week ×3 months) with loss of control and marked distress, without compensatory behaviors.[15]
- Female-to-male ratio is approximately 1.75:1, narrower than for bulimia nervosa.[1]
- Roughly half of patients with BED have obesity; about half do not — diagnosis is independent of body mass index.[3-4]
- DSM-5-TR severity is rated by weekly binge frequency: mild 1–3, moderate 4–7, severe 8–13, extreme ≥14.[15]
- First-line treatment is cognitive behavioral therapy (CBT-E), with abstinence rates near 50% at end of treatment.[13,28]
- lisdexamfetamine is the only FDA-approved pharmacotherapy for moderate-to-severe BED in adults.[14]
- topiramate reduces binge frequency and weight but is limited by cognitive adverse effects and teratogenicity.[26]
- SSRIs reduce binge frequency modestly; effect is smaller than in bulimia nervosa and may not persist after discontinuation.[9]
- ADHD is overrepresented in BED; treating comorbid ADHD can improve binge outcomes.[5]
- Lisdexamfetamine carries a boxed warning for stimulant misuse and cardiovascular risk; screen for structural heart disease before prescribing.[14]
- Bupropion is relatively contraindicated when purging is suspected because of seizure risk; clarify the diagnosis before prescribing.[21]
- Twin-study heritability of BED is approximately 40–60%.[10]
- Childhood emotional abuse and weight-related teasing are robust prospective risk factors.[6,11]
- ICD-11 allows subjective binges and does not require the 3-month duration threshold used by DSM-5-TR.[16]
No external funding. No conflicts of interest declared. Peer-review status: pending.
- 1.Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348-358. doi:10.1016/j.biopsych.2006.03.040. PMID: 16815322.PMID: 16815322doi:10.1016/j.biopsych.2006.03.040
- 2.Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904-914. doi:10.1016/j.biopsych.2012.11.020. PMID: 23290497.PMID: 23290497doi:10.1016/j.biopsych.2012.11.020
- 3.Mitchell JE, King WC, Courcoulas A, et al. Eating behavior and eating disorders in adults before bariatric surgery. Int J Eat Disord. 2015;48(2):215-222. doi:10.1002/eat.22275. PMID: 24719222.PMID: 24719222doi:10.1002/eat.22275
- 4.Kornstein SG. Epidemiology and recognition of binge-eating disorder in psychiatry and primary care. J Clin Psychiatry. 2017;78(suppl 1):3-8. doi:10.4088/JCP.sh16003su1c.01. PMID: 28125174.PMID: 28125174doi:10.4088/JCP.sh16003su1c.01
- 5.Cortese S, Bernardina BD, Mouren M-C. Attention-deficit/hyperactivity disorder (ADHD) and binge eating. Nutr Rev. 2007;65(9):404-411. doi:10.1111/j.1753-4887.2007.tb00318.x. PMID: 17958207.PMID: 17958207doi:10.1111/j.1753-4887.2007.tb00318.x
- 6.Forrest LN, Zuromski KL, Dodd DR, Smith AR. Suicidality in adolescents and adults with binge-eating disorder: results from the National Comorbidity Survey Replication and Adolescent Supplement. Int J Eat Disord. 2017;50(1):40-49. doi:10.1002/eat.22582. PMID: 27436772.PMID: 27436772doi:10.1002/eat.22582
- 7.Olguin P, Fuentes M, Gabler G, Guerdjikova AI, Keck PE Jr, McElroy SL. Medical comorbidity of binge eating disorder. Eat Weight Disord. 2017;22(1):13-26. doi:10.1007/s40519-016-0313-5. PMID: 27553016.PMID: 27553016doi:10.1007/s40519-016-0313-5
- 8.Kessler RM, Hutson PH, Herman BK, Potenza MN. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev. 2016;63:223-238. doi:10.1016/j.neubiorev.2016.01.013. PMID: 26850211.PMID: 26850211doi:10.1016/j.neubiorev.2016.01.013
- 9.Systematic reviewStefano SC, Bacaltchuk J, Blay SL, Appolinario JC. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav. 2008;9(2):129-136. doi:10.1016/j.eatbeh.2007.03.006. PMID: 18329590.PMID: 18329590doi:10.1016/j.eatbeh.2007.03.006
- 10.Yilmaz Z, Hardaway JA, Bulik CM. Genetics and epigenetics of eating disorders. Adv Genomics Genet. 2015;5:131-150. doi:10.2147/AGG.S55776. PMID: 27013903.PMID: 27013903doi:10.2147/AGG.S55776
- 11.TextbookStice E, Marti CN, Rohde P. Prevalence, incidence, impairment, and course of the proposed DSM-5 eating disorder diagnoses in an 8-year prospective community study of young women. J Abnorm Psychol. 2013;122(2):445-457. doi:10.1037/a0030679. PMID: 23148784.PMID: 23148784doi:10.1037/a0030679
- 12.Becker CB, Middlemass K, Taylor B, Johnson C, Gomez F. Food insecurity and eating disorder pathology. Int J Eat Disord. 2017;50(9):1031-1040. doi:10.1002/eat.22735. PMID: 28626944.PMID: 28626944doi:10.1002/eat.22735
- 13.Systematic reviewHilbert A, Petroff D, Herpertz S, et al. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. J Consult Clin Psychol. 2019;87(1):91-105. doi:10.1037/ccp0000358. PMID: 30570304.PMID: 30570304doi:10.1037/ccp0000358
- 14.RCTMcElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-246. doi:10.1001/jamapsychiatry.2014.2162. PMID: 25587645.PMID: 25587645doi:10.1001/jamapsychiatry.2014.2162
- 15.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 16.TextbookWorld Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: WHO; 2019/2022.
- 17.Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry. 2014;48(11):977-1008. doi:10.1177/0004867414555814. PMID: 25351912.PMID: 25351912doi:10.1177/0004867414555814
- 18.Mehler PS, Brown C. Anorexia nervosa - medical complications. J Eat Disord. 2015;3:11. doi:10.1186/s40337-015-0040-8. PMID: 25834735.PMID: 25834735doi:10.1186/s40337-015-0040-8
- 19.Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry. 1998;59(1):14-19. PMID: 9491060.PMID: 9491060
- 20.TextbookStahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
- 21.National Institute for Health and Care Excellence. Eating disorders: recognition and treatment (NG69). London: NICE; 2017.
- 22.GuidelineLock J, La Via MC; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with eating disorders. J Am Acad Child Adolesc Psychiatry. 2015;54(5):412-425. doi:10.1016/j.jaac.2015.01.018. PMID: 25901778.PMID: 25901778doi:10.1016/j.jaac.2015.01.018
- 23.Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994;16(4):363-370. PMID: 7866415.PMID: 7866415
- 24.Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. Addict Behav. 1982;7(1):47-55. doi:10.1016/0306-4603(82)90024-7. PMID: 7080884.PMID: 7080884doi:10.1016/0306-4603(82)90024-7
- 25.Herman BK, Deal LS, DiBenedetti DB, Nelson L, Fehnel SE, Brown TM. Development of the 7-Item Binge-Eating Disorder Screener (BEDS-7). Prim Care Companion CNS Disord. 2016;18(2):10.4088/PCC.15m01896. doi:10.4088/PCC.15m01896. PMID: 27486545.PMID: 27486545doi:10.4088/PCC.15m01896
- 26.RCTMcElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039-1048. doi:10.1016/j.biopsych.2006.08.008. PMID: 17258690.PMID: 17258690doi:10.1016/j.biopsych.2006.08.008
- 27.Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes Metab Syndr. 2020;14(4):289-292. doi:10.1016/j.dsx.2020.03.009. PMID: 32289741.PMID: 32289741doi:10.1016/j.dsx.2020.03.009
- 28.Systematic reviewLinardon J, Wade TD, de la Piedad Garcia X, Brennan L. The efficacy of cognitive-behavioral therapy for eating disorders: a systematic review and meta-analysis. J Consult Clin Psychol. 2017;85(11):1080-1094. doi:10.1037/ccp0000245. PMID: 29083223.PMID: 29083223doi:10.1037/ccp0000245
- 29.RCTSafer DL, Robinson AH, Jo B. Outcome from a randomized controlled trial of group therapy for binge eating disorder: comparing dialectical behavior therapy adapted for binge eating to an active comparison group therapy. Behav Ther. 2010;41(1):106-120. doi:10.1016/j.beth.2009.01.006. PMID: 20171333.PMID: 20171333doi:10.1016/j.beth.2009.01.006
- 30.RCTDalton B, Bartholdy S, McClelland J, et al. Randomised controlled feasibility trial of real versus sham repetitive transcranial magnetic stimulation treatment in adults with severe and enduring anorexia nervosa and binge-eating disorder. PLoS One. 2018;13(3):e0193075. doi:10.1371/journal.pone.0193075. PMID: 29554102.PMID: 29554102doi:10.1371/journal.pone.0193075
More on these topics
Pica: Diagnosis, Workup, and Management
A clinical reference on pica covering DSM-5-TR criteria, iron-deficiency workup, pregnancy and developmental considerations, and behavioral treatment.
Child & Adolescent PsychiatryFeeding and Eating DisordersPicaFeeding and Eating Disorders: Diagnosis, Assessment, and Evidence-Based Management
A clinical reference on anorexia nervosa, bulimia nervosa, binge-eating disorder, and ARFID — diagnosis, medical risks, and treatment.
Binge-Eating DisorderAnorexia NervosaBulimia NervosaEncopresis: Diagnosis, Evaluation, and Treatment in Children
A clinical reference on encopresis in children covering DSM-5-TR criteria, retentive versus nonretentive subtypes, evaluation, and a stepwise disimpaction-maintenance-behavioral treatment plan.
Elimination DisordersChild & Adolescent PsychiatryEncopresisDepersonalization/Derealization Disorder: Clinical Recognition, Differential Diagnosis, and Management
A clinical reference on depersonalization/derealization disorder, covering DSM-5-TR criteria, assessment, differential diagnosis, and evidence-based management.
Dissociative DisordersAnxiety DisordersPsychopharmacologyKleptomania: Clinical Features, Differential Diagnosis, and Evidence-Based Treatment
A clinical reference on kleptomania covering DSM-5-TR criteria, comorbidity, differential diagnosis, and pharmacologic and behavioral treatment.
PsychopharmacologyDifferential DiagnosisKleptomaniaIntermittent Explosive Disorder: Diagnosis, Neurobiology, and Evidence-Based Management
A clinical reference on intermittent explosive disorder covering DSM-5-TR criteria, neurobiology, differential, and the evidence base for SSRI and CBT treatment.
Disruptive, Impulse-Control, and Conduct DisordersPsychopharmacologyIntermittent Explosive DisorderDepressive Disorder Due to Another Medical Condition
A clinical guide to diagnosing and treating depression caused by a general medical condition, with criteria, workup, and evidence-based management.
Depressive Disorder Due to Another Medical ConditionPicaSubstance/Medication-Induced Depressive Disorder
A clinical reference on substance- and medication-induced depressive disorder — diagnosis, common culprits, work-up, and management.
PsychopharmacologySubstance/Medication-Induced Depressive Disorder